Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX-PAD in Muscle Injury Following Hip Fracture Arthroplasty
NCT03451916Phase 3Completed
- Sponsor
- Pluri Inc.
- Start
- Jul 2018
- Primary completion
- Apr 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in muscle injury comparing PLX-PAD with Placebo (2 arms). Primary endpoint: Short Physical Performance Battery at 26 weeks. Started Jul 2018; status: completed.
02
Drugs
PLX-PAD
03
Conditions
muscle injury
Beyond the preview
Go deeper on NCT03451916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03451916.